KR20210111770A - 조작된 플라겔린-유래 조성물 및 용도 - Google Patents

조작된 플라겔린-유래 조성물 및 용도 Download PDF

Info

Publication number
KR20210111770A
KR20210111770A KR1020217021065A KR20217021065A KR20210111770A KR 20210111770 A KR20210111770 A KR 20210111770A KR 1020217021065 A KR1020217021065 A KR 1020217021065A KR 20217021065 A KR20217021065 A KR 20217021065A KR 20210111770 A KR20210111770 A KR 20210111770A
Authority
KR
South Korea
Prior art keywords
amino acid
flagellin
flagellin variant
acid residue
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217021065A
Other languages
English (en)
Korean (ko)
Inventor
바딤 메트
안드레이 구드코브
Original Assignee
게놈 프로텍션 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게놈 프로텍션 인코포레이티드 filed Critical 게놈 프로텍션 인코포레이티드
Publication of KR20210111770A publication Critical patent/KR20210111770A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020217021065A 2018-12-07 2019-12-06 조작된 플라겔린-유래 조성물 및 용도 Ceased KR20210111770A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776507P 2018-12-07 2018-12-07
US62/776,507 2018-12-07
PCT/US2019/064954 WO2020118192A1 (en) 2018-12-07 2019-12-06 Engineered flagellin-derived compositions and uses

Publications (1)

Publication Number Publication Date
KR20210111770A true KR20210111770A (ko) 2021-09-13

Family

ID=70974397

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217021065A Ceased KR20210111770A (ko) 2018-12-07 2019-12-06 조작된 플라겔린-유래 조성물 및 용도

Country Status (10)

Country Link
US (1) US20220024991A1 (cg-RX-API-DMAC7.html)
EP (1) EP3890769A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022511881A (cg-RX-API-DMAC7.html)
KR (1) KR20210111770A (cg-RX-API-DMAC7.html)
CN (1) CN113382742A (cg-RX-API-DMAC7.html)
AU (1) AU2019392903A1 (cg-RX-API-DMAC7.html)
CA (1) CA3122067A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191610A1 (cg-RX-API-DMAC7.html)
IL (1) IL283757A (cg-RX-API-DMAC7.html)
WO (1) WO2020118192A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024085375A1 (ko) * 2022-10-19 2024-04-25 전남대학교산학협력단 Tlr5 활성능을 가진 플라젤린 면역증강제 유도체의 진핵세포 발현시스템을 이용한 제조 및 응용
WO2024106866A1 (ko) * 2022-11-14 2024-05-23 전남대학교 산학협력단 암의 치료용 면역증강 살모넬라 균주 및 이의 용도

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102720967B1 (ko) * 2020-06-04 2024-10-23 가톨릭대학교 산학협력단 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 면역관문억제제의 항암 효과 증진용 약학 조성물
CN119522108A (zh) * 2022-06-01 2025-02-25 弗莱格生物公司 Rna佐剂、其方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121734B1 (en) * 2007-02-09 2013-05-08 Industry Foundation of Chonam National University Modified flagellin improved toll-like receptor 5 stimulating activity
US9376495B2 (en) * 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
CA2903252C (en) * 2013-03-14 2023-01-17 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
EP3174893B1 (en) * 2014-07-30 2020-05-06 Genome Protection, Inc. Flagellin compositions and uses

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024085375A1 (ko) * 2022-10-19 2024-04-25 전남대학교산학협력단 Tlr5 활성능을 가진 플라젤린 면역증강제 유도체의 진핵세포 발현시스템을 이용한 제조 및 응용
WO2024106866A1 (ko) * 2022-11-14 2024-05-23 전남대학교 산학협력단 암의 치료용 면역증강 살모넬라 균주 및 이의 용도

Also Published As

Publication number Publication date
CA3122067A1 (en) 2020-06-11
US20220024991A1 (en) 2022-01-27
IL283757A (en) 2021-07-29
EA202191610A1 (ru) 2021-10-25
CN113382742A (zh) 2021-09-10
AU2019392903A1 (en) 2021-06-24
JP2022511881A (ja) 2022-02-01
EP3890769A4 (en) 2022-11-23
EP3890769A1 (en) 2021-10-13
WO2020118192A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
US10669316B2 (en) Flagellin compositions and uses
JP7312706B2 (ja) 血液悪性腫瘍に対するcd47標的化治療のための投与パラメータ
US20220024991A1 (en) Engineered flagellin-derived compositions and uses
JP2011149961A (ja) 骨髄およびリンパ系細胞癌の診断および処置
JP2022522775A (ja) Lilrb4結合抗体およびその使用方法
EP3980463A1 (en) Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
WO2016014899A1 (en) Flagellin derivatives and uses
US20250145715A1 (en) B7-h3 targeting fusion proteins and methods of use thereof
JP2025179057A (ja) 併用療法のための患者の選択
US20080153746A1 (en) Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers
JP2022539038A (ja) 骨髄細胞炎症性表現型を調節するための抗lrrc25組成物及び方法、ならびにその使用
WO2020163692A1 (en) Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway
HK1237803A1 (en) Flagellin compositions and uses
HK1237803B (en) Flagellin compositions and uses
HK40050163B (en) Selection of patients for combination therapy
HK40050163A (en) Selection of patients for combination therapy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601